choriogonadotropin alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5149	177073-44-8

Description:

Molecule	Description
Synonyms: choriogonadotropin alfa ovidrel ovitrelle	Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

choriogonadotropin alfa
ovidrel
ovitrelle

Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.25	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 20, 2000	FDA	EMD SERONO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	4262.25	48.42	605	2730	2639	50599150
Ascites	736.70	48.42	209	3126	35652	50566137
Ovarian haemorrhage	188.72	48.42	30	3305	282	50601507
Maternal exposure before pregnancy	181.53	48.42	47	3288	5550	50596239
Inappropriate schedule of product administration	157.50	48.42	82	3253	71749	50530040
Adnexal torsion	151.60	48.42	24	3311	219	50601570
Pelvic fluid collection	129.72	48.42	25	3310	758	50601031
Ovarian enlargement	123.90	48.42	22	3313	420	50601369
Haemoperitoneum	120.61	48.42	29	3306	2526	50599263
Pleural effusion	93.09	48.42	61	3274	81393	50520396
Abortion spontaneous	86.57	48.42	46	3289	41726	50560063
Multiple pregnancy	76.64	48.42	11	3324	47	50601742
Abdominal distension	72.24	48.42	50	3285	72853	50528936
Effusion	69.52	48.42	17	3318	1586	50600203
Intra-abdominal haemorrhage	68.82	48.42	18	3317	2202	50599587
Ectopic pregnancy	67.98	48.42	18	3317	2309	50599480
Abdominal pain lower	65.85	48.42	31	3304	21725	50580064
Ovarian cyst ruptured	55.37	48.42	13	3322	1020	50600769
Poor response to ovulation induction	51.77	48.42	6	3329	0	50601789
Infrequent bowel movements	49.00	48.42	12	3323	1126	50600663

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product packaging quantity issue	189.27	85.61	28	448	737	29573314
No adverse event	145.27	85.61	37	439	17441	29556610
Product dose omission issue	124.19	85.61	49	427	96334	29477717

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	3753.34	50.25	510	2457	2335	64493430
Ascites	655.30	50.25	199	2768	61802	64433963
Ovarian haemorrhage	186.04	50.25	28	2939	265	64495500
Adnexal torsion	157.63	50.25	23	2944	172	64495593
Pelvic fluid collection	143.43	50.25	25	2942	623	64495142
Ovarian enlargement	138.70	50.25	22	2945	301	64495464
Maternal exposure before pregnancy	111.71	50.25	27	2940	3456	64492309
Haemoperitoneum	98.61	50.25	25	2942	3890	64491875
Pleural effusion	83.94	50.25	59	2908	126500	64369265
Multiple pregnancy	75.30	50.25	10	2957	33	64495732
Effusion	72.14	50.25	17	2950	1951	64493814
Ovarian cyst ruptured	62.39	50.25	13	2954	848	64494917
Abdominal distension	55.01	50.25	41	2926	95953	64399812
Abdominal pain lower	54.91	50.25	26	2941	26443	64469322
Intra-abdominal haemorrhage	51.12	50.25	15	2952	4016	64491749

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03GA08	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Gonadotropins
FDA CS	M0009540	Gonadotropins
FDA EPC	N0000175838	Gonadotropin

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Lutropin-choriogonadotropic hormone receptor	GPCR	P22888	LSHR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
6413W06WR3	UNII
4021245	VANDF
C0937609	UMLSCUI
CHEMBL1201464	ChEMBL_ID
D03478	KEGG_DRUG
DB00097	DRUGBANK_ID
7473	INN_ID
C412828	MESH_SUPPLEMENTAL_RECORD_UI
283550	RXNORM
15777	MMSL
38355	MMSL
129494006	SNOMEDCT_US
391878002	SNOMEDCT_US
009029	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ovidrel	HUMAN PRESCRIPTION DRUG LABEL	1	44087-1150	INJECTION, SOLUTION	250 ug	SUBCUTANEOUS	BLA	23 sections